Shared Versus Unique Features of Neural Activation During Cognitive Flexibility Across Restrictive Eating Disorder Presentations
Abstract
Objective: Restrictive eating disorders (EDs), including anorexia nervosa (AN) and atypical AN (Atyp-AN), are often associated with cognitive rigidity that can impede treatment. The dorsolateral prefrontal cortex (dlPFC) plays a central role in cognitive control, but it remains unclear whether its activation during cognitive flexibility will differ across restrictive ED presentations.
Method: Eighty-seven females with restrictive EDs (aged 14-35) (AN: n = 31; atyp-AN with history of AN [hx-AN]: n = 33; atyp-AN without history of AN [Atyp-AN]: n = 23) completed a task-switching paradigm during functional magnetic resonance imaging. We examined dlPFC activation during sustained (task-switching vs. completing a single task) and transient control (switching between task rules vs. repeating the same rule), testing for group differences and symptom associations.
Results: The AN group showed a greater difference in left dlPFC activation during task switching vs. the single task compared to the hx-AN and Atyp-AN groups, driven by reduced activation during the single task condition. All groups showed similar increases in dlPFC activation during task switching and no differences in task performance. Across all participants, higher dlPFC activation during task switching vs. single task was associated with greater restraint symptoms.
Discussion: These novel findings identified shared versus unique neural features of sustained and transient control across restrictive ED groups.…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 33 participants or records.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.